| Year |
Citation |
Score |
| 2023 |
Rafii MS, Fortea J. Down Syndrome in a New Era for Alzheimer Disease. Jama. PMID 37991807 DOI: 10.1001/jama.2023.22924 |
0.354 |
|
| 2023 |
Rissman RA, Langford O, Raman R, Donohue MC, Abdel-Latif S, Meyer MR, Wente-Roth T, Kirmess KM, Ngolab J, Winston CN, Jimenez-Maggiora G, Rafii MS, Sachdev P, West T, Yarasheski KE, et al. Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37932961 DOI: 10.1002/alz.13542 |
0.694 |
|
| 2023 |
Leisher S, Bohorquez A, Gay M, Garcia V, Jones R, Baldaranov D, Rafii MS. Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer's Disease. Cns Drugs. PMID 37470978 DOI: 10.1007/s40263-023-01021-8 |
0.415 |
|
| 2023 |
Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, van Dyck CH, Iwatsubo T, Marshall GA, Yaari R, Mancini M, Holdridge KC, Case M, Sims JR, Aisen PS. Trial of Solanezumab in Preclinical Alzheimer's Disease. The New England Journal of Medicine. PMID 37458272 DOI: 10.1056/NEJMoa2305032 |
0.571 |
|
| 2023 |
Rafii MS, Aisen PS. Detection and treatment of Alzheimer's disease in its preclinical stage. Nature Aging. 3: 520-531. PMID 37202518 DOI: 10.1038/s43587-023-00410-4 |
0.602 |
|
| 2023 |
Baldaranov D, Garcia V, Miller G, Donohue MC, Shaw LM, Weiner M, Petersen RC, Aisen P, Raman R, Rafii MS. Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease. Alzheimer's & Dementia (Amsterdam, Netherlands). 15: e12431. PMID 37091309 DOI: 10.1002/dad2.12431 |
0.552 |
|
| 2022 |
Boerwinkle AH, Gordon BA, Wisch J, Flores S, Henson RL, Butt OH, McKay N, Chen CD, Benzinger TLS, Fagan AM, Handen BL, Christian BT, Head E, Mapstone M, Rafii MS, et al. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study. The Lancet. Neurology. 22: 55-65. PMID 36517172 DOI: 10.1016/S1474-4422(22)00408-2 |
0.413 |
|
| 2022 |
Rafii MS, Sperling RA, Donohue MC, Zhou J, Roberts C, Irizarry MC, Dhadda S, Sethuraman G, Kramer LD, Swanson CJ, Li D, Krause S, Rissman RA, Walter S, Raman R, et al. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 35971310 DOI: 10.1002/alz.12748 |
0.718 |
|
| 2022 |
Rafii MS, Sol O, Mobley WC, Delpretti S, Skotko BG, Burke AD, Sabbagh MN, Yuan SH, Rissman RA, Pulsifer M, Evans C, Evans AC, Beth G, Fournier N, Gray JA, et al. Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial. Jama Neurology. PMID 35532913 DOI: 10.1001/jamaneurol.2022.0983 |
0.558 |
|
| 2022 |
Aisen PS, Jimenez-Maggiora GA, Rafii MS, Walter S, Raman R. Early-stage Alzheimer disease: getting trial-ready. Nature Reviews. Neurology. PMID 35379951 DOI: 10.1038/s41582-022-00645-6 |
0.587 |
|
| 2021 |
Fortea J, Zaman SH, Hartley S, Rafii MS, Head E, Carmona-Iragui M. Alzheimer's disease associated with Down syndrome: a genetic form of dementia. The Lancet. Neurology. 20: 930-942. PMID 34687637 DOI: 10.1016/S1474-4422(21)00245-3 |
0.404 |
|
| 2021 |
Ngolab J, Donohue M, Belsha A, Salazar J, Cohen P, Jaiswal S, Tan V, Gessert D, Korouri S, Aggarwal NT, Alber J, Johnson K, Jicha G, van Dyck C, Lah J, ... ... Rafii MS, et al. Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial. Alzheimer's & Dementia (Amsterdam, Netherlands). 13: e12199. PMID 34430703 DOI: 10.1002/dad2.12199 |
0.706 |
|
| 2021 |
Sperling R, Henley D, Aisen PS, Raman R, Donohue MC, Ernstrom K, Rafii MS, Streffer J, Shi Y, Karcher K, Raghavan N, Tymofyeyev Y, Bogert J, Brashear HR, Novak G, et al. Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial. Jama Neurology. PMID 33464300 DOI: 10.1001/jamaneurol.2020.4857 |
0.53 |
|
| 2020 |
Petersen ME, Rafii MS, Zhang F, Hall J, Julovich D, Ances BM, Schupf N, Krinsky-McHale SJ, Mapstone M, Silverman W, Lott I, Klunk W, Head E, Christian B, Foroud T, et al. Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. Journal of Alzheimer's Disease : Jad. PMID 33337378 DOI: 10.3233/JAD-201167 |
0.369 |
|
| 2020 |
Rafii MS, Ances BM, Schupf N, Krinsky-McHale SJ, Mapstone M, Silverman W, Lott I, Klunk W, Head E, Christian B, Lai F, Rosas HD, Zaman S, Petersen ME, Strydom A, et al. The AT(N) framework for Alzheimer's disease in adults with Down syndrome. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12062. PMID 33134477 DOI: 10.1002/dad2.12062 |
0.418 |
|
| 2020 |
Rafii MS, Aisen PS. The search for Alzheimer disease therapeutics - same targets, better trials? Nature Reviews. Neurology. PMID 32963375 DOI: 10.1038/s41582-020-00414-3 |
0.527 |
|
| 2020 |
Santoro JD, Pagarkar D, Chu DT, Rosso M, Paulsen KC, Levitt P, Rafii MS. Neurologic complications of Down syndrome: a systematic review. Journal of Neurology. PMID 32920658 DOI: 10.1007/s00415-020-10179-w |
0.368 |
|
| 2020 |
Walter S, Langford OG, Clanton TB, Jimenez-Maggiora GA, Raman R, Rafii MS, Shaffer EJ, Sperling RA, Cummings JL, Aisen PS. The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD): Experience from the First 3 Years. The Journal of Prevention of Alzheimer's Disease. 7: 234-241. PMID 32920625 DOI: 10.14283/jpad.2020.47 |
0.598 |
|
| 2020 |
Jimenez-Maggiora GA, Bruschi S, Raman R, Langford O, Donohue M, Rafii MS, Sperling RA, Cummings JL, Aisen PS. TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology. The Journal of Prevention of Alzheimer's Disease. 7: 226-233. PMID 32920624 DOI: 10.14283/jpad.2020.48 |
0.534 |
|
| 2020 |
Walter S, Clanton TB, Langford OG, Rafii MS, Shaffer EJ, Grill JD, Jimenez-Maggiora GA, Sperling RA, Cummings JL, Aisen PS. Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD). The Journal of Prevention of Alzheimer's Disease. 7: 219-225. PMID 32920623 DOI: 10.14283/jpad.2020.46 |
0.579 |
|
| 2020 |
Petersen ME, Zhang F, Schupf N, Krinsky-McHale SJ, Hall J, Mapstone M, Cheema A, Silverman W, Lott I, Rafii MS, Handen B, Klunk W, Head E, Christian B, Foroud T, et al. Proteomic profiles for Alzheimer's disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS) study. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12039. PMID 32626817 DOI: 10.1002/Dad2.12039 |
0.468 |
|
| 2020 |
Craft S, Raman R, Chow TW, Rafii MS, Sun CK, Rissman RA, Donohue MC, Brewer JB, Jenkins C, Harless K, Gessert D, Aisen PS. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial. Jama Neurology. PMID 32568367 DOI: 10.1001/Jamaneurol.2020.1840 |
0.76 |
|
| 2020 |
Snyder HM, Bain LJ, Brickman AM, Carrillo MC, Esbensen AJ, Espinosa JM, Fernandez F, Fortea J, Hartley SL, Head E, Hendrix J, Kishnani PS, Lai F, Lao P, Lemere C, ... ... Rafii MS, et al. Further understanding the connection between Alzheimer's disease and Down syndrome. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 32544310 DOI: 10.1002/Alz.12112 |
0.486 |
|
| 2020 |
Rafii MS. Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials. Cns Drugs. PMID 32506291 DOI: 10.1007/s40263-020-00740-6 |
0.54 |
|
| 2020 |
Donohue MC, Model F, Delmar P, Volye N, Liu-Seifert H, Rafii MS, Aisen PS. Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 32270600 DOI: 10.1002/Alz.12058 |
0.557 |
|
| 2019 |
van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, et al. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial. Jama Neurology. PMID 31329216 DOI: 10.1001/Jamaneurol.2019.2050 |
0.741 |
|
| 2019 |
Iddi S, Li D, Aisen PS, Rafii MS, Thompson WK, Donohue MC. Predicting the course of Alzheimer's progression. Brain Informatics. 6: 6. PMID 31254120 DOI: 10.1186/S40708-019-0099-0 |
0.567 |
|
| 2019 |
Rafii MS, Donohue MC, Matthews DC, Muranevici G, Ness S, O'Bryant SE, Rissman RA. Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). Journal of Alzheimer's Disease : Jad. PMID 31156181 DOI: 10.3233/JAD-190322 |
0.661 |
|
| 2019 |
Craft S, Raman R, Chow TW, Rafii MS, Rissman RA, Brewer JB, Donohue MC, Sun C, Harless K, Gessert D, Aisen PS. DT-02-03: OPEN LABEL EXTENSION RESULTS FROM A PHASE II/III TRIAL OF INTRANASAL INSULIN Alzheimer's & Dementia. 15: P1489-P1489. DOI: 10.1016/J.Jalz.2019.08.012 |
0.6 |
|
| 2018 |
Rafii MS, Aisen PS. Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention. Cns Drugs. PMID 30560544 DOI: 10.1007/S40263-018-0598-1 |
0.63 |
|
| 2018 |
Rafii MS. Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome. Developmental Neurobiology. PMID 30536948 DOI: 10.1002/dneu.22658 |
0.528 |
|
| 2018 |
Li D, Iddi S, Thompson WK, Rafii MS, Aisen PS, Donohue MC. Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & Dementia (Amsterdam, Netherlands). 10: 657-668. PMID 30456292 DOI: 10.1016/J.Dadm.2018.07.008 |
0.608 |
|
| 2018 |
Rafii MS, Santoro SL. Prevalence and Severity of Alzheimer Disease in Individuals With Down Syndrome. Jama Neurology. PMID 30452497 DOI: 10.1001/jamaneurol.2018.3443 |
0.431 |
|
| 2018 |
Rafii MS. Diagnostic biomarkers of Alzheimer's disease in Down syndrome. The Lancet. Neurology. PMID 30172623 DOI: 10.1016/S1474-4422(18)30293-X |
0.469 |
|
| 2018 |
Iddi S, Li D, Aisen PS, Rafii MS, Litvan I, Thompson WK, Donohue MC. Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative. Neuro-Degenerative Diseases. 18: 173-190. PMID 30089306 DOI: 10.1159/000488780 |
0.546 |
|
| 2018 |
Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Rissman RA, Siffert J, Aisen PS. Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial. Jama Neurology. PMID 29582053 DOI: 10.1001/Jamaneurol.2018.0233 |
0.742 |
|
| 2017 |
Rafii MS, Lukic AS, Andrews RD, Brewer J, Rissman RA, Strother SC, Wernick MN, Pennington C, Mobley WC, Ness S, Matthews DC. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). Journal of Alzheimer's Disease : Jad. 60: 439-450. PMID 28946567 DOI: 10.3233/Jad-170390 |
0.747 |
|
| 2017 |
Carmona-Iragui M, Balasa M, Benejam B, Alcolea D, Fernández S, Videla L, Sala I, Sánchez-Saudinos MB, Morenas-Rodriguez E, Ribosa-Nogué R, Illán-Gala I, Gonzalez-Ortiz S, Clarimón J, Schmitt F, Powell DK, ... ... Rafii M, et al. Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28463681 DOI: 10.1016/J.Jalz.2017.03.007 |
0.521 |
|
| 2017 |
Rafii MS, Skotko BG, McDonough ME, Pulsifer M, Evans C, Doran E, Muranevici G, Kesslak P, Abushakra S, Lott IT. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia. Journal of Alzheimer's Disease : Jad. PMID 28453471 DOI: 10.3233/JAD-160965 |
0.525 |
|
| 2017 |
Esbensen AJ, Hooper SR, Fidler D, Hartley SL, Edgin J, d'Ardhuy XL, Capone G, Conners FA, Mervis CB, Abbeduto L, Rafii M, Krinsky-McHale SJ, Urv T, Group OMW. Outcome Measures for Clinical Trials in Down Syndrome. American Journal On Intellectual and Developmental Disabilities. 122: 247-281. PMID 28452584 DOI: 10.1352/1944-7558-122.3.247 |
0.317 |
|
| 2017 |
Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. PMID 28381506 DOI: 10.1212/Wnl.0000000000003904 |
0.784 |
|
| 2017 |
Rafii M. OBSERVATIONAL AND INTERVENTIONAL CLINICAL TRIALS FOR AD IN DS: LESSONS LEARNED AND FUTURE DIRECTIONS Alzheimer's & Dementia. 13: P1212. DOI: 10.1016/j.jalz.2017.07.379 |
0.382 |
|
| 2016 |
Matthews DC, Lukic AS, Andrews RD, Marendic B, Brewer J, Rissman RA, Mosconi L, Strother SC, Wernick MN, Mobley WC, Ness S, Schmidt ME, Rafii MS. Dissociation of Down syndrome and Alzheimer's disease effects with imaging. Alzheimer's & Dementia (New York, N. Y.). 2: 69-81. PMID 28642933 DOI: 10.1016/J.Trci.2016.02.004 |
0.767 |
|
| 2016 |
Rafii MS. Targeting tau protein in Alzheimer's disease. Lancet (London, England). PMID 27863808 DOI: 10.1016/S0140-6736(16)32107-9 |
0.465 |
|
| 2016 |
Rafii MS. Improving Memory and Cognition in Individuals with Down Syndrome. Cns Drugs. PMID 27272473 DOI: 10.1007/s40263-016-0353-4 |
0.489 |
|
| 2016 |
Matthews DC, Lukic AS, Andrews RD, Marendic B, Brewer J, Rissman RA, Mosconi L, Strother SC, Wernick MN, Mobley WC, Ness S, Schmidt ME, Rafii MS. Dissociation of Down syndrome and Alzheimer's disease effects with imaging Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2: 69-81. DOI: 10.1016/j.trci.2016.02.004 |
0.671 |
|
| 2015 |
Rafii MS. Active Immunotherapy for Alzheimer's Disease: The Road Ahead. The Journal of Prevention of Alzheimer's Disease. 2: 78-79. PMID 28331846 DOI: 10.14283/jpad.2015.59 |
0.369 |
|
| 2015 |
Rafii MS, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, Aisen PS, Rissman RA. The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. Frontiers in Behavioral Neuroscience. 9: 239. PMID 26441570 DOI: 10.3389/Fnbeh.2015.00239 |
0.771 |
|
| 2015 |
Rafii MS, Aisen PS. Advances in Alzheimer's disease drug development. Bmc Medicine. 13: 62. PMID 25857341 DOI: 10.1186/S12916-015-0297-4 |
0.664 |
|
| 2014 |
Vellas B, Sampaio C, Bateman R, Boxer A, Carrillo MC, Cummings J, Dubois B, Hampel H, Katz R, Khachaturian Z, Gauthier S, Johnson K, Karlawish J, Mintun M, Petersen R, ... Rafii M, et al. EU./U.S. CTAD Task Force on Alzheimer's Trial Populations. The Journal of Prevention of Alzheimer's Disease. 1: 110-116. PMID 29255837 DOI: 10.14283/jpad.2014.6 |
0.585 |
|
| 2014 |
Rafii MS. Pro: Are we ready to translate Alzheimer's disease modifying therapies to people with Down syndrome? Alzheimer's Research & Therapy. 6: 60. PMID 25478025 DOI: 10.1186/s13195-014-0060-7 |
0.532 |
|
| 2014 |
Rafii MS. Preclinical Alzheimer's disease therapeutics. Journal of Alzheimer's Disease : Jad. 42: S545-9. PMID 25079804 DOI: 10.3233/JAD-141482 |
0.525 |
|
| 2014 |
Rafii MS, Baumann TL, Bakay RA, Ostrove JM, Siffert J, Fleisher AS, Herzog CD, Barba D, Pay M, Salmon DP, Chu Y, Kordower JH, Bishop K, Keator D, Potkin S, et al. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: 571-81. PMID 24411134 DOI: 10.1016/J.Jalz.2013.09.004 |
0.445 |
|
| 2014 |
Rafii MS, Taylor CS, Kim HT, Desikan RS, Fleisher AS, Katibian D, Brewer JB, Dale AM, Aisen PS. Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias. 29: 159-65. PMID 24164929 DOI: 10.1177/1533317513507373 |
0.736 |
|
| 2013 |
Rafii MS. Update on Alzheimer's disease therapeutics. Reviews On Recent Clinical Trials. 8: 110-8. PMID 23859061 DOI: 10.2174/15748871113089990045 |
0.521 |
|
| 2013 |
Desikan RS, Rafii MS, Brewer JB, Hess CP. An expanded role for neuroimaging in the evaluation of memory impairment. Ajnr. American Journal of Neuroradiology. 34: 2075-82. PMID 23764728 DOI: 10.3174/ajnr.A3644 |
0.645 |
|
| 2012 |
Ness S, Rafii M, Aisen P, Krams M, Silverman W, Manji H. Down's syndrome and Alzheimer's disease: Towards secondary prevention Nature Reviews Drug Discovery. 11: 655-656. PMID 22935789 DOI: 10.1038/Nrd3822 |
0.603 |
|
| 2012 |
Rafii MS. Advances in the Treatment of Alzheimer's Disease Molecular and Cellular Therapeutics. 233-244. DOI: 10.1002/9781119967309.ch10 |
0.37 |
|
| 2011 |
Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 76: 1389-94. PMID 21502597 DOI: 10.1212/Wnl.0B013E318216Eb7B |
0.579 |
|
| 2011 |
Rafii M, Taylor C, Coutinho A, Kim K, Galasko D. Comparison of the memory performance index with standard neuropsychological measures of cognition American Journal of Alzheimer's Disease and Other Dementias. 26: 235-239. PMID 21406427 DOI: 10.1177/1533317511402316 |
0.581 |
|
| 2010 |
Rafii MS, Brewer JB. Functional brain imaging in the clinical assessment of consciousness. Plos Biology. 8: e1000548. PMID 21151340 DOI: 10.1371/journal.pbio.1000548 |
0.553 |
|
| 2010 |
Rafii MS. The pulse of drug development for Alzheimer's disease. Reviews On Recent Clinical Trials. 5: 57-62. PMID 20205688 DOI: 10.2174/157488710790820490 |
0.524 |
|
| 2009 |
Kovacevic S, Rafii MS, Brewer JB. High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment. Alzheimer Disease and Associated Disorders. 23: 139-45. PMID 19474571 DOI: 10.1097/WAD.0b013e318192e745 |
0.615 |
|
| 2009 |
Rafii MS, Aisen PS. Recent developments in Alzheimer's disease therapeutics. Bmc Medicine. 7: 7. PMID 19228370 DOI: 10.1186/1741-7015-7-7 |
0.632 |
|
| 2009 |
Shankle WR, Aisen P, Fleisher A, Petersen R, Ferris SH, Rafii M, Smith J. Reducing noise in the ADAS-COG wordlist task Alzheimers & Dementia. 5: 161. DOI: 10.1016/J.Jalz.2009.05.556 |
0.376 |
|
| 2008 |
Rafii MS, Galasko D. Primary care screening for dementia and mild cognitive impairment. Jama. 299: 1132; author reply 1. PMID 18334686 DOI: 10.1001/jama.299.10.1132-a |
0.565 |
|
| 2006 |
Rafii MS, Hagiwara H, Mercado ML, Seo NS, Xu T, Dugan T, Owens RT, Hook M, McQuillan DJ, Young MF, Fallon JR. Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development. Journal of Cellular Physiology. 209: 439-47. PMID 16883602 DOI: 10.1002/Jcp.20740 |
0.551 |
|
| 2006 |
Mercado ML, Amenta AR, Hagiwara H, Rafii MS, Lechner BE, Owens RT, McQuillan DJ, Froehner SC, Fallon JR. Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 20: 1724-6. PMID 16807372 DOI: 10.1096/Fj.05-5124Fje |
0.684 |
|
| 2006 |
Ravindranath PA, Kavatkar M, Rafii MS, Aisen PS, Jimenez-Maggiora G. P1-345: CLASSIFICATION OF EMOTIONAL RESPONSES IN VIDEO AND AUDIO RECORDINGS USING A CONVOLUTIONAL NEURAL NETWORK Alzheimer's & Dementia. 14: P426-P426. DOI: 10.1016/J.Jalz.2018.06.352 |
0.38 |
|
| 2006 |
Ravindranath PA, Raman R, Chow TW, Rafii MS, Aisen PS, Jimenez-Maggiora G. P3-014: DEEP LEARNING IN AUTOMATED CLASSIFICATION OF ADVERSE EVENTS IN CLINICAL STUDIES OF ALZHEIMER'S DISEASE Alzheimer's & Dementia. 14: P1067-P1068. DOI: 10.1016/j.jalz.2018.06.1369 |
0.486 |
|
| 2006 |
Ravindranath PA, Hong P, Rafii MS, Aisen PS, Jimenez-Maggiora G. P2-571: A STEP FORWARD IN INTEGRATING HEALTHCARE AND VOICE-ENABLED TECHNOLOGY: CONCEPT DEMONSTRATION WITH DEPLOYMENT OF AUTOMATIC MEDICAL CODING MODEL AS AN AMAZON “ALEXA” SKILL Alzheimer's & Dementia. 14: P955-P955. DOI: 10.1016/J.Jalz.2018.06.1266 |
0.382 |
|
| 2006 |
Ravindranath PA, Raman R, Chow TW, Rafii MS, Aisen PS, Jimenez-Maggiora G. TD-P-016: DEEP LEARNING IN AUTOMATED CLASSIFICATION OF ADVERSE EVENTS IN CLINICAL STUDIES OF ALZHEIMER'S DISEASE Alzheimer's & Dementia. 14: P193-P193. DOI: 10.1016/J.Jalz.2017.06.1871 |
0.546 |
|
| 2000 |
Berzin TM, Zipser BD, Rafii MS, Kuo-Leblanc V, Yancopoulos GD, Glass DJ, Fallon JR, Stopa EG. Agrin and microvascular damage in Alzheimer's disease. Neurobiology of Aging. 21: 349-55. PMID 10867220 DOI: 10.1016/S0197-4580(00)00121-4 |
0.681 |
|
| 1999 |
Donahue JE, Berzin TM, Rafii MS, Glass DJ, Yancopoulos GD, Fallon JR, Stopa EG. Agrin in Alzheimer's disease: altered solubility and abnormal distribution within microvasculature and brain parenchyma. Proceedings of the National Academy of Sciences of the United States of America. 96: 6468-72. PMID 10339611 DOI: 10.1073/Pnas.96.11.6468 |
0.677 |
|
| Show low-probability matches. |